An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection
Latest Information Update: 07 May 2015
At a glance
- Drugs Sofosbuvir (Primary) ; Peginterferon; Ribavirin
- Indications Hepatitis C
- Focus Expanded access; Therapeutic Use
- Sponsors Gilead Sciences
- 07 Feb 2013 New trial record